5-Fluorocytosine Intermediate Supplied by Experienced Chemical Manufacturer for Global Distribution

Mechanism of Action – Fungal Selective Toxicity

5‑FC is a prodrug that requires intracellular conversion to its active metabolites. The selective toxicity against fungi (and certain bacteria) hinges on the enzyme cytosine deaminase, which is present in susceptible microorganisms but absent in human cells.

• Step 1 – Uptake: 5‑FC enters fungal cells via cytosine permease, a transporter not present in mammalian cells.

• Step 2 – Deamination: Fungal cytosine deaminase converts 5‑FC to 5‑fluorouracil (5‑FU).

• Step 3 – Further metabolism: 5‑FU is then converted to 5‑fluorouridine monophosphate (5‑FUMP) and subsequently to 5‑fluorouridine triphosphate (5‑FUTP) and 5‑fluorodeoxyuridine monophosphate (5‑FdUMP).

• Step 4 – Toxic effects:

  • 5‑FUTP incorporates into fungal RNA, causing miscoding and inhibition of protein synthesis.

  • 5‑FdUMP inhibits thymidylate synthase, blocking DNA synthesis by depleting dTMP.

These dual actions – disrupting both RNA and DNA – result in potent fungistatic (and at higher concentrations, fungicidal) activity.

Clinical Applications – Always in Combination

5‑FC is never used as monotherapy due to rapid development of resistance (mutation rates of 10⁻⁶ to 10⁻⁷). Its primary indications are serious systemic fungal infections, always combined with another antifungal, most commonly amphotericin B or fluconazole.

• Cryptococcal meningitis: 5‑FC is a cornerstone of induction therapy. The combination of amphotericin B plus 5‑FC for the first two weeks is superior to amphotericin alone, leading to faster cerebrospinal fluid sterilization and lower mortality. In resource‑limited settings, fluconazole plus 5‑FC is used when amphotericin is unavailable.

• 
  

• Candidiasis: For deep‑seated candidal infections (e.g., candida endocarditis, meningitis, or hepatosplenic candidiasis), 5‑FC combined with amphotericin B or an echinocandin is recommended. It is also used for Candida glabrata infections when other agents fail.

• 
  

• Chromoblastomycosis: 5‑FC combined with itraconazole or terbinafine is a treatment option for this chronic subcutaneous fungal infection.

• 
  

• Other rare mycoses: It has activity against Aspergillus (synergistic with amphotericin) and Penicillium marneffei.

• 
  

Pharmacokinetics and Dosing

• Absorption: Well absorbed orally (bioavailability 75–90%), reaching peak serum concentrations 2–4 hours after dosing.

• Dosing: Typical dose is 100–150 mg/kg/day divided into four doses (every 6 hours). Dose must be adjusted for renal function.

• Distribution: Excellent penetration into cerebrospinal fluid (60–80% of serum levels), making it ideal for central nervous system infections.

• Elimination: Excreted unchanged in urine (over 90%). Half‑life is 2.5–5 hours in normal renal function but extends significantly in renal impairment.

• 
  

Adverse Effects and Monitoring

The most serious toxicity is bone marrow suppression (leukopenia, thrombocytopenia, anemia), caused by conversion of 5‑FC to 5‑FU in mammalian bone marrow cells. This is dose‑dependent and particularly common when serum levels exceed 100 mg/L. Other effects include:

• Gastrointestinal: Nausea, vomiting, diarrhea (dose‑related).

• Hepatotoxicity: Elevated liver enzymes, occasionally hepatitis.

• Renal toxicity: Rare directly, but often co‑administered with amphotericin B, which is nephrotoxic.

Contraindications and Drug Interactions

• Contraindications: Hypersensitivity, bone marrow failure (unless strictly necessary), severe renal impairment without dose adjustment.

• Interactions: Cytotoxic drugs (e.g., cytarabine) increase myelosuppression. Drugs affecting renal function (amphotericin, aminoglycosides) elevate 5‑FC levels.

• 
  

Resistance Mechanisms
Resistance emerges rapidly during monotherapy due to mutations in:

• Cytosine permease (reduced uptake).

• Cytosine deaminase (reduced conversion to 5‑FU).

• Upregulation of pyrimidine synthesis pathways.

This is why combination therapy is mandatory.

5‑Fluorocytosine is a narrow‑spectrum antifungal that, despite its age (discovered in 1950s), remains indispensable for life‑threatening infections like cryptococcal meningitis. Its requirement for combination therapy and its myelosuppressive potential demand careful monitoring, but when used correctly, it saves lives in situations where few alternatives exist.